Mass rollout of weight loss jabs begins on NHS

Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years.
The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested.
From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems.
Patients previously needed to access the drugs through a special weight loss service.
But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout.
And pharmacy experts also said there could be pressure on supplies of the drug.
In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea.
Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription.
Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.
'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people.
'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions.
'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'
Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments.
'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow.
GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack.
Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪
🔗Learn more: https://t.co/GY4a7VRAgF pic.twitter.com/Agiav8ryfU
— EU Medicines Agency (@EMA_News) January 4, 2025
She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely.
'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss.
'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.'
Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'.
She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.'
Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately.
'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly.
'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy.
'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice.
'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it.
'The biggest concern we have is that prescribing these medications alone misses the point.
'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up.
'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.'
Around 29% of the adult population in the UK is obese.
Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity.
'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

The Sun

2 hours ago

• The Sun

Deborah James' dad calls for NHS cancer revolution in letter to Government

DAME Deborah James' dad has backed calls for Wes Streeting to end cancer diagnosis and treatment delays, warning 'there is no time to lose'. Alistair James issued a plea for the Health Secretary to overhaul NHS care with the upcoming cancer strategy. 4 4 4 He has signed an open letter led by Cancer Research UK that calls for faster diagnosis, waiting time targets to be met, smoking reduction and more equal access to treatment. Sun columnist Dame Debs died in 2022 after a years-long battle with bowel cancer. Her Bowelbabe charity fund has since raised £17million for research and a laboratory at the prestigious Francis Crick Institute was recently named after the mum-of-two. Dad Alistair said: 'Three years ago this week, Deborah died at the age of 40 from bowel cancer. 'I am so proud that her legacy continues through the fantastic Bowelbabe Fund. 'Too many people are waiting too long to be diagnosed and treated for bowel cancer. 'And the percentage of cancers being diagnosed at an early stage, when there is a greater chance of survival, has hardly changed for almost a decade. 'We have an opportunity to shape the next decade of the government's plans for cancer and you can help make a difference by signing Cancer Research UK's open letter to the Health Secretary, Wes Streeting.' 4 The letter to Mr Streeting has already been signed by 5,500 people. It said: 'Nearly 1 in 2 of us will get cancer in our lifetimes, and across England, cancer cases are increasing, patients face unacceptable waits and unequal access to treatment. 'In 2024 alone, 74,000 people in England were not treated on time for cancer. 'People with cancer deserve better. They need better. 'There is no time to waste.' Sign the letter online at

The Independent

2 hours ago

• The Independent

Mounjaro weight loss jabs now available from GPs

The NHS in England is set to begin a mass rollout of the anti-obesity drug Mounjaro (tirzepatide) on Monday, with GPs allowed to prescribe it for the first time. The initiative is expected to reach approximately 220,000 severely obese people with multiple health complications across England over the next three years. Eligibility for the drug includes a body mass index (BMI) over 40 and at least four other obesity-linked health problems, such as type 2 diabetes or high blood pressure. Leading family doctors have raised concerns about the additional workload and training implications for GPs associated with the new rollout. Pharmacy experts anticipate potential pressure on drug supplies and say that the medication should be part of a comprehensive weight management strategy, not a standalone solution.

Daily Mirror

2 hours ago

• Daily Mirror

EastEnders' Samantha Womack's heartbreaking change after breast cancer battle

Former EastEnders actress Samantha Womack is living her best life in Spain with her Emmerdale partner, and exclusively reveals her incredible transformation after cancer Chatting from her home in Spain's Valencia mountains, with only her rescue dogs for company, former EastEnders actress Samantha Womack couldn't sound happier. The 52-year-old underwent gruelling treatment for breast cancer after being diagnosed in August 2022, but says she now believes the experience has changed her outlook on life for the better. 'I feel so much more enlightened,' says the Brighton-born star. 'I know myself better, I feel humbler, I feel calmer.' The biggest day-to-day change to Samantha's life is that she works far less – although for an actress who's worked pretty much non-stop since rising to fame representing the UK at Eurovision in 1991 and then launching her acting career in the mid-1990s in Pie In The Sky and Game On, saying no doesn't come easily. ‌ ‌ 'After my year-and-a-half of treatment, I started turning down a lot of stuff – and I didn't have the bank balance to match that confidence, trust me,' admits the actress, who announced she was cancer-free in December 2022. 'It was me saying the word 'no' and my bank account creaking. But there was empowerment in that because I thought, 'OK, I need to go through this, spend time with myself and figure out stuff that I've never figured out – maybe stuff I've buried under a rug.'' Another of Samantha's post-cancer convictions is the need for women's health – particularly breast health – to be more of a priority. She received her diagnosis after a private check-up, driven by a gut feeling that she needed to be seen. 'I felt perfectly fine. There was no discolouration of skin, dimpling, irritation,' she recalls. 'I knew the NHS calls people in at 50, but I just had this thought of, 'I need to go and get checked before then.' I was just on the cusp of catching it too late and the speed with which I had to process information was unbearable. I sometimes think, 'What if I hadn't gone to that appointment?'' Samantha learned she had a fast-spreading, Grade 3 invasive duct carcinoma and her treatment – a lumpectomy and lymph node removal, followed by chemotherapy and radiotherapy – couldn't wait. As the stepdaughter of a GP, she threw herself into researching breast health. One of the most shocking things she discovered was the number of women who don't receive accurate mammogram results because of their breast density level. The denser the breast, meaning there is more fibroglandular tissue, the greater the risk of cancer and the harder it is for mammograms to detect tumours. The star, who is mum to Benjamin, 24, and Lili-Rose, 20, her children with her ex-husband Mark Womack, concluded that women mustn't put their health at the bottom of their 'to do' list. 'We all live in busy worlds and tend to put these little niggles to one side,' she says. 'I'm an avid lover of the NHS, but if something is worrying you and you have the money to go and get yourself checked, why would you not? I did and it changed my life. Now, I want to empower women to take control of their bodies.' ‌ Samantha recognises her privilege, but admits her finances today are very different from the days when she played Ronnie Mitchell in EastEnders from 2007-2017. 'Soaps pay very, very well, but the reality of being self-employed means that, yes, you get paid for the jobs you do, but for the six months of the year you don't work, you don't get paid,' she says. 'I've never been a wealthy person. I've gone from job to job, always thinking, 'Better say yes because no one's going to want me if I don't.' I had very low self-esteem. Going back to work after my treatment felt very hard. I couldn't quite step back into that neurotic, zany energy as easily. I was physically capable, but I wasn't emotionally capable. I was picking things that felt gentle to me.' One of those gentle jobs was a guest role in cosy crime series The Marlow Murder Club, which, she says, involved a 'lovely bunch of women' and 'felt like a safe space'. ‌ 'Now it's about things I feel I can emotionally connect to, without having to lose myself too much,' she says. 'I'm not ready to go into a gold lamé dress and boogie about on stage.' Another big change for Samantha is how much time she spends alone, as her partner, actor Oliver Farnworth, 42, splits his time between Spain and the UK, where he plays John Sugden in Emmerdale. The set-up works well, she explains. 'He comes back for two or three days at a time, but is filming a lot at the moment. That's been quite good for me, having some space on my own. It's been rare in my life that I've been confident enough to do that, so it's been helpful.' Last year, the actress hinted she and Oliver were considering becoming parents together. 'We've talked about adopting, because after the cancer treatment I wouldn't be able to conceive naturally and because of my age,' she says. 'But I think I'm learning to put things in perspective and hopefully, in the next 10 years, one of my kids will produce a sproglet and I can go from maternal to gra-ternal!'